SEC-sourced researchBeta
CCCC
C4 Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001662579
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Oct 2, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 35,584,000.0000 | Feb 26, 2026 |
| December 2025 | 35,947,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 35,947,000.0000 | -104,994,000.0000 | -98,694,000.0000 | 359,075,000.0000 | 102,488,000.0000 | Feb 26, 2026 |
| December 2024 | 35,584,000.0000 | -105,316,000.0000 | -65,157,000.0000 | 349,602,000.0000 | 133,616,000.0000 | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $35.95M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $35.58M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$104.99M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$98.69M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $359.08M | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $102.49M | December 2025 | Feb 26, 2026 | 10-K |